Genomics

Dataset Information

0

Pyruvate Anaplerosis is a Targetable Vulnerability in Persistent Leukaemic Stem Cells


ABSTRACT: Deregulated oxidative metabolism is a hallmark of leukaemia. While use of tyrosine kinase inhibitors (TKIs) such as imatinib has led to increased survival of chronic myeloid leukaemia (CML) patients, it fails to eradicate disease initiating leukemic stem cells (LSCs). Whether TKI-treated CML LSCs remain metabolically deregulated is unknown. Using clinically and physiologically relevant assays we generated multi-omics datasets that offer unprecedented insight into nutrient fate in patient derived CML LSCs. We demonstrate that LSCs have increased glucose anaplerosis when compared to normal hematopoietic stem cells. While imatinib treatment reverses BCR-ABL-mediated LSC metabolic reprogramming, stable isotope-assisted metabolomics revealed that deregulated glucose anaplerosis is unaffected by imatinib. Encouragingly, genetic ablation of glucose anaplerosis sensitises CML cells to imatinib. Finally, we demonstrate that the clinical oral-available inhibitor MSDC-0160 targets glucose anaplerosis in robust pre-clinical CML models. Collectively these results highlight glucose anaplerosis as a persistent and therapeutically targetable vulnerability in imatinib-treated CML patient samples.

ORGANISM(S): Homo sapiens

PROVIDER: GSE216837 | GEO | 2023/06/27

REPOSITORIES: GEO

Similar Datasets

2023-05-03 | GSE218451 | GEO
2011-05-17 | E-GEOD-29347 | biostudies-arrayexpress
2010-11-15 | E-GEOD-21986 | biostudies-arrayexpress
2014-06-03 | E-GEOD-48294 | biostudies-arrayexpress
2021-05-23 | GSE175323 | GEO
2012-07-05 | E-GEOD-36096 | biostudies-arrayexpress
2008-10-21 | E-GEOD-12211 | biostudies-arrayexpress
2022-11-14 | GSE198576 | GEO
2022-03-27 | GSE199304 | GEO
2009-12-01 | GSE17480 | GEO